Purpose: To evaluate the midterm anatomical and functional outcomes of intravitreal injection of low-dose triamcinolone acetonide in silicone oil-filled eyes as an adjunctive treatment for proliferative vitreoretinopathy.
P
roliferative vitreoretinopathy (PVR) is characterized by the formation of contractile membranes within the vitreous and along the epiretinal and subretinal surfaces. 1 It is a common complication of rhegmatogenous retinal detachment (RRD) and ocular trauma, and a major cause of redetachment after RD surgery. 1 Over the years, progress has been made in the management of PVR. Silicone oil (SO) tamponade serves to hold the retina flat against the wall of the eye, preventing the migration of fibroblasts and growth factors, and therefore inhibits proliferation. 2 Drugs such as triamcinolone acetonide (TA) can reduce inflammatory reaction and proliferative response. Over the past two decades, intravitreal triamcinolone acetonide (IVTA) has been used as an adjunct to vitrectomy in treating and preventing PVR. 3, 4 Previous studies showed that IVTA could be used in eyes with PVR undergoing vitrectomy with SO tamponade yielding good retinal reattachment rate and visual improvement. The dosages of IVTA used were typically 4 mg or higher. 5, 6 However, the complications arising from IVTA, such as glaucoma, cataract, infection, and reduction of scleral wound healing, may reduce the anatomical and functional success, especially after SO removal. 7, 8 The optimal dosage has not been well delineated. Our group 9 previously studied the safety and efficacy of using 4, 6, and 8 mg of IVTA in treating diabetic macular edema. Higher dosages were associated not only with slightly higher efficacy but also with a higher complication rate, especially ocular hypertension. In the literature, the dosages of IVTA used for treating diabetic macular edema were reported to range from 2 mg to 40 mg. 10 We also have had experience with using 2 mg of IVTA in patients with diabetic macular edema, branch or central retinal vein occlusion, and intermediate uveitis, especially for those who had higher risks of developing steroidinduced ocular hypertension. The side effects especially ocular hypertension appeared to be lower. We chose 2 mg of IVTA in this study because such a low dose has not been studied in PVR before.
In this study, we reported the midterm anatomical and functional results of 37 eyes of 37 patients with PVR secondary to RRD or ocular trauma who received pars plana vitrectomy, SO tamponade, and 2 mg of IVTA with sequential SO removal.
Methods

Patients
This was a retrospective interventional case series conducted at the Joint Shantou International Eye Center of the Shantou University and the Chinese University of Hong Kong. The study was approved by the institutional review board of Joint Shantou International Eye Center. The medical records were searched, and the potential candidates of all eyes receiving surgeries for PVR between February 2006 and May 2007 were reviewed retrospectively. Patients aged .18 years, with PVR grade C or D 11 secondary to RRD or ocular trauma who underwent vitrectomy, membrane peeling combined with 2 mg of IVTA, and SO tamponade were included in this study.
Technique
All operations were performed under sub-Tenon's anesthesia by one of us (W.C.). Sutureless 20G pars plana vitrectomy was performed with 1.2-mm tunnel sclerotomies. 12 Posterior vitreous cortex and epiretinal membrane were removed and peeled off, respectively. Perfluorodecalin (Huajieshi, Shanghai, China) was injected into the vitreous cavity to stabilize the retina. Laser photocoagulation or transscleral cryopexy was performed on the area of retinal tears or peripheral retinal degeneration. After gas-fluid exchange, intravitreal injection of 2 mg of TA (Kenacort; BristolMyers Squibb, Sermoneta, Italy) in 0.05 mL (without purification) was followed by SO (Oxane 5700; Bausch & Lomb, Waterford, Ireland) injection.
Phacoemulsification was performed in the same stage as the vitrectomy in 30 eyes, and 22 of them had intraocular lens implantation. Releasing 360°retinet-omy was performed followed by laser photocoagulation in 2 cases that had severe anterior PVR.
Silicone Oil Removal
After sub-Tenon's anesthesia, emulsified SO in the anterior chamber, if any, was removed by irrigation and aspiration. Three-port pars plana sclerotomies were made as in traditional 20G vitrectomy. The SO was removed by vacuum using a 10-mL syringe. Gasfluid exchange was carried out 3 times and was followed by anterior chamber irrigation and aspiration again. Peripheral retina was examined with scleral indentation, and laser photocoagulation or cryopexy was applied to areas of peripheral retinal degeneration or retinal break. Gas tamponade of 16% C 3 F 8 was carried out after gas-fluid exchange if necessary.
Outcome Measures and Statistical Analysis
The patients were followed-up after surgery. Visual acuity, intraocular pressure (IOP), retinal status, and complications were recorded in each visit. Primary outcome measures were retinal reattachment rate and the best-corrected visual acuity (BCVA). Retinal reattachment was defined as complete reattachment of the retina without any localized detachment. The presence of extensive proliferation in an attached retina also is considered to be successful. Visual acuity was converted to logMAR units for analysis. Paired t-test was used to compare the BCVA before and after surgery. Visual acuity increase or decrease was defined as difference of logMAR 0.3 or more after surgery compared with baseline. Secondary outcome measures included IOP and complications. SPSS version 16.0 (SPSS, Chicago, IL) was used to conduct the statistical analysis.
Results
In all, 37 eyes of 37 patients were included in this study (Tables 1 and 2 ). The mean age was 46.5 6 13.9 years (range, 19-74 years). There were 25 men and 12 women. The PVR was secondary to RRD in 32 eyes and ocular trauma in 5 eyes. Five eyes previously had scleral laceration repair, three had received scleral buckling, and two had vitrectomy combined with C 3 F 8 or SO tamponade. Preoperatively one eye was pseudophakic, five eyes had choroidal detachment, and seven eyes had peripheral retinal break combined with macular hole.
After vitrectomy with SO tamponade and IVTA, the patients were followed-up for a mean period of 7.9 6 2.7 months (range, 4-17 months) before SO removal. Retina remained attached in 36 (97.3%) patients at the last visit. There was redetachment in 1 (3.7%) eye because of recurrence of PVR. The mean BCVA was 1.76 6 0.56 at baseline, and improved to 1.30 6 0.47 at the last visit after vitrectomy (P , 0.001). Of the six remaining phakic eyes after vitrectomy, five remained cataract free while one had recurrent PVR and RD with total lens opacity. Six eyes had elevated IOP of .21 mmHg and 3 of them were .25 mmHg. Silicone oil emulsification was noted in four eyes. Triamcinolone acetonide could be seen in 5 eyes at 1 month after the vitrectomy, and they were no longer present at 2 months after surgery.
All patients received SO removal after a mean follow-up period of 7.9 months. During the oil removal surgery, combined laser photocoagulation or cryopexy and C 3 F 8 tamponade was carried out in four eyes, laser photocoagulation alone was applied in one eye. After SO removal, the patients were followed-up for 15.0 6 9.5 months (range, 1-34 months); therefore, the patients were followed-up for a total duration of 22.9 6 9.6 months (range, 10-42 months). One case developed retinal redetachment because of peripheral retinal break 3 days after SO removal and was repaired by cryopexy and C 3 F 8 
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tamponade. The retina of 36 eyes remained reattached at the last visit. The mean BCVA improved from 1.30 6 0.47 before SO removal to 0.87 6 0.60 at the last visit after SO removal (P , 0.001). The difference in BCVA at the final visit and baseline is statistically significant (P , 0.001). When the BCVA at last visit after SO removal was compared with the vision at baseline, it was increased in 31 (83.8%) eyes, remained the same in 5 (13.5%) eyes, and decreased in 1 (2.7%) eye ( Figure 1 , Table 3 ). There was only 1 case whose IOP was .21 mmHg at the final visit. One case developed 1-mm hypopyon 1 day after surgery, but culture for anterior chamber aspiration was negative. The hypopyon resolved after anterior chamber washout and intravitreal injection of vancomycin. There were some cases of mild to moderate peri-SO proliferation and macular pucker, and all of them were removed during the SO removal surgery.
After SO removal, two of the five phakic eyes remained cataract free; mild to moderate lens opacity was developed in two eyes at the last visit.
Discussion
We have shown in this retrospective study that intravitreal injection of 2 mg of triamcinolone as an adjunct to vitrectomy and SO tamponade in treating PVR (grade C or D) is effective and safe. Although we have all the faults of a retrospective study, this is the first study on using a low dose (2 mg) of triamcinolone, which may have some advantages over the standard dosage of 4 mg. Moreover, we have a relatively long mean follow-up period of 22.9 6 9.6 months. Furthermore, removal of SO was performed in all study eyes (100%), and a high retinal reattachment rate (97.3%) was achieved.
In 2000, Jonas et al 5 first reported the use of adjunctive IVTA in eyes with PVR undergoing vitrectomy and SO tamponade. They injected 16 eyes with 10 mg to 20 mg of triamcinolone. Retinae of majority (81.2%) of cases remained attached without SO removal after a follow-up period of 1.64 months. Later on, Munir et al 6 reported the use of 4 mg of IVTA with 57.1% retina reattachment rate and 28.6% visual acuity improvement rate. Cheema et al 13 reported 87.5% reattachment rate, and visual acuity improved in 100% of the eyes 11 months after vitrectomy, SO tamponade, and 4 mg of IVTA. In 2008, Ahmadieh et al 14 reported an 84.2% reattachment rate and an improvement of visual acuity by 0.9 logMAR units 6 months after 4 mg of triamcinolone adjunctive to vitrectomy and SO tamponade in the first stage and SO removal in the second stage. They found that the results were not significantly different from the control group in which no IVTA was used. Table 4 is a summary of the results of the current and previous studies reported in the literature on using IVTA as adjunctive treatment for PVR receiving vitrectomy and SO tamponade. In our study, low dose (2 mg) of triamcinolone was used, the patients were followed-up for a longer duration, and all patients received sequential SO removal. We obtained better anatomical success rate (97.3% retinal reattachment rate) than previous studies (57.1% to 87.5%). The BCVA of our patients significantly improved, and this is comparable with results reported in previous studies. Corticosteroids have long been known to reduce intraocular inflammation and suppress cellular proliferation. These have been used in ophthalmology as early as the 1950s. 15, 16 Triamcinolone acetonide is a lipophilic corticosteroid with low solubility in aqueous solution. Because of the advantageous pharmacokinetic profile with rapid bioavailability and sustained-release characteristics, IVTA was introduced into clinical use in 1979. 3, 4 Since then, IVTA has become an increasingly popular treatment of severe ocular diseases such as uveitis, 17 macular edema, 18 age-related macular degeneration, 19 and PVR. 20 It has been suggested that combined TA and SO in vitrectomy can treat and prevent recurrence of PVR, resulting in good anatomical retinal reattachment rate and functional recovery. However, the pharmacokinetic characteristics of TA in SO might differ from when they are in a liquid. Triamcinolone is not soluble in SO, and the TA crystals might become sediment at the lower border of the SO bubble and a very high concentration could be built up, which could be harmful to retinal cells. 21, 22 Jonas 23 reported that TA could still be detected in SO 8 months after intravitreal injection of TA in SO-filled eyes. Triamcinolone acetonide can inhibit not only inflammation and proliferative response in PVR but also the inflammation required for healing. The long-standing high concentration of steroids may compromise the healing of retinal breaks, hence causing redetachment after SO removal. Higher dose of TA may also cause increased IOP and cataract. Therefore, the low dose of TA (2 mg) used in this study might have been a contributing factor to the better anatomical result in our case series.
Both SO and TA may cause cataract, and cataract surgery might be required later. 7, 8 Moreover, the anterior PVR cannot be completely removed during vitrectomy in phakic eyes and might result in retinal redetachment. 24, 25 Furthermore, visually significant cataracts developed in a considerable number of phakic eyes after pars plana vitrectomy; therefore, combined cataract and vitreous surgeries offer the advantages of a single procedure with faster recovery time and improved cost-effectiveness. 26 In this study, 30 of 37 eyes received cataract surgery, and 24 of these had intraocular lens implantation during the primary operation of vitrectomy.
Both TA and SO may cause an increase of IOP. The effect of TA on IOP is dependent on its concentration. This was another reason why we used a lower dose of triamcinolone. It was reported that IOP increased by 5 mmHg in 30% of patients within 3 months after IVTA injection, and most of them normalized gradually within 6 months. However, some patients who received high-dose injection may need surgical intervention. 8, 27, 28 Silicone oil tamponade may cause IOP elevation, and in most cases, IOP can be normalized after oil removal. 29 In our case series, there were 3 cases with IOP .25 mmHg after vitrectomy. These cases may be because of emulsification or excess SO filling. Therefore, we used repeated gas-fluid exchange and repeated anterior chamber irrigation and aspiration to remove the SO completely. The IOP in all of these cases returned to normal after SO removal except one, and it could be controlled by topical medicine.
All of the subjects in our study were Chinese. The effect of IVTA on different ethnicity is unclear. However, we postulate that pigmented races might have a more pronounced healing response based on the experience from trabeculectomy. Therefore, the degree of PVR might be more severe in Chinese than in whites, and the use of IVTA could potentially be more useful in pigmented races. Larger trials incorporating different races with subgroup analysis might provide such information.
The limitations in our study include all the faults of a retrospective study, the lack of a control group, small sample size, lack of full data on the lens and posterior capsule status, and extent of PVR in terms of clock hours. Additionally, the majority of eyes in this study were primary PVR. Only 5 (15.6%) of the 32 eyes that had primary RRD had received surgical treatment procedures previously. This is significantly lower than the 56.3% to 84.2%, reported in the literature by other studies. 5, 6, 13 The eyes with primary PVR may have better outcomes than those that have multiple earlier vitreoretinal procedures. This may be part of the reason explaining better results in this study comparing with reports in the literature.
In summary, vitrectomy with 2 mg of IVTA and SO tamponade for PVR resulted in 97.3% anatomical success rate, and the mean BCVA improved from 1.76 to 0.87. These procedures appear to be effective and safe for the treatment of PVR. Further, a large sample size and randomized control trial is needed to confirm the findings in this study.
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